Upconversion-based photon-initiated therapeutic modalities, photodynamic therapy (PDT) in particular, have shown significant clinical potential in deep-seated tumor treatment. However, traditional multiphoton upconversion materials involving lanthanide (ion)-doped upconversion nanoparticles (UCNPs) and two-photon absorption (TPA) dyes often suffer from lots of inherent problems such as unknown systematic toxicity, low reproducibility, and extremely high irradiation intensity for realization of multiphoton upconversion excitation. Herein, for the first time, we report a one-photon excitation molecular photosensitizer (FUCP-1) based on a frequency upconversion luminescence (FUCL) mechanism. Under anti-Stokes (808 nm) excitation, FUCP-1 showed excellent photostability and outstanding upconversion luminescence quantum yield (up to 12.6%) for imaging-guided PDT. In vitro cellular toxicity evaluation presented outstanding inhibition of 4T1 cells by FUCP-1 with 808 nm laser irradiation (the half maximal inhibitory concentration was as low as 2.06 mM). After intravenous injection, FUCP-1 could specifically accumulate at tumor sites and obviously suppress the growth of deep-seated tumors during PDT. More importantly, FUCP-1 could be fully metabolized from the body within 24 h, thus dramatically minimizing systemic toxicity. This study might pave a new way for upconversion-based deep-seated cancer PDT.
Introduction
Photodynamic therapy (PDT), a clinically approved noninvasive cancer treatment modality, has attracted considerable attention in recent years. [1] [2] [3] [4] PDT agents, also known as photosensitizers (PSs), are generally nontoxic to nonirradiated normal cells and become highly toxic in tumor cells under selective irradiation of the tumor region through generating singlet oxygen ( 1 O 2 ) or reactive free radicals. 5 Most conventional PSs (e.g., ZnPc, PPIX, etc.) are responsive to visible light (400-700 nm); thus, PDT is typically triggered by using visible light. 6, 7 However, the tissue penetration limitation of short-wavelength light caused by strong absorption of melanin and hemoglobin in the visible region is problematic for the widespread clinical use of PDT.
7-11
In contrast, near-infrared (NIR) light in the "therapeutic window" (700-900 nm) can effectively penetrate into deeper tissue and causes less photodamage.
12-14 Therefore, it is desirable to realize deep PDT using NIR light, which is of great importance for further clinical applications.
Current efforts have been focused on the red-shi of organic PSs to the NIR region for deep-tissue PDT. However, these compounds are always difficult to synthesize and display bad anti-bleaching capabilities during NIR light irradiation. 7, 15, 16 Furthermore, as the photon energy of NIR light rapidly decreases above 800 nm, few NIR organic molecules hold promise for effectively generating cytotoxic reactive oxygen species (ROS) and killing tumor cells, especially the deep-seated ones.
17,18
To overcome these "Achilles' heels", upconversion strategies which can convert low-energy long-wavelength photons to highenergy short-wavelength emission light have become the focus of deep-seated cancer PDT recently. 7 In particular, lanthanidebased multiphoton upconversion nanoparticles (UCPNs) that give rise to ultraviolet-visible light when the lanthanide ions in excited states absorb energies from two or more NIR photons (Scheme 1, le) and then sensitize PSs through a uorescence resonance energy transfer (FRET) process to generate cytotoxic ROS have presented great potential in deep-seated tumor PDT. a superior in vivo tumor imaging effect due to their specic optical properties, such as better tissue penetration depth, large anti-Stokes shi, high signal-to-noise ratio (SNR), and negligible autouorescence from biological organization.
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However, the well-known low reproducibility, potential longterm toxicity and unclear systematic clearance of these upconversion nano-materials may limit their further clinical application. [23] [24] [25] [26] Besides, current clinical and experimental data show that the enormous diameters of nano-materials make it difficult for them to penetrate into tumor tissues from blood, leading to a poor PDT effect. [27] [28] [29] [30] [31] [32] In addition, non-degradable inorganic nanoparticles through intravenous injection into animal models can unexpectedly promote the intravasation and extravasation of cancer cells. 33 In comparison, organic small molecular PSs feature outstanding merits such as superior biosafety, precise synthesis, and optimal reproducibility, and thus, developing organic molecular upconversion PSs may be of more clinical benet for cancer therapy.
Alternatively, two-photon absorption (TPA) molecular dyes are another commonly used candidate for deep PDT based on the upconversion mechanism. During the TPA process, a virtual level occurs because of the interaction of photons and dye molecules (Scheme 1, middle). 19 However, the probability of TPA occurring is very low as the virtual level does not really exist. And thus, the realization of two-photon excitation always needs extremely high energy from a femtosecond laser, which can irreversibly damage cells and tissues. Besides, two-photon excitation only occurs at the focus of the high-intensity laser, which makes deep-tissue PDT impractical, because a laser beam will defocus while passing through tissue. 34 These limitations seriously hinder the in vivo application of TPA PSs. Therefore, the exploitation of new molecular PSs with a more biocompatible upconversion strategy is greatly desired.
As a potential alternative, frequency upconversion luminescence (FUCL) which is a typical one-photon process, offers a new opportunity for the realization of deep PDT. This FUCL phenomenon was rst discovered by Wood in 1928. 27 Early investigations of the FUCL technology were mainly concentrated on the study of the photophysical process, laser cooling and thermal imaging. Quite recently, Li et al. used FUCL compounds for the detection of MeHg + and Cu
2+
, further expanding the application of the FUCL technology. 35, 36 Compared to the multiphoton upconversion mechanism including lanthanide-based f-f transition and TPA, FUCL can be realized when a molecule in the thermally vibrational-rotational state (S t ) absorbs less energy (hv < hv f < nhv, n $ 2) from only one photon (Scheme 1, right). 7, 24, 37 Moreover, the thermally vibrational-rotational state (S t ) is a real intermediate state, and thus the probability of occurrence of hot band absorption and reaching the excited state (S 1 ) has a much higher degree than that of TPA. Therefore, these types of organic molecules may be more promising for biological applications, especially deepseated tumor treatment. Unfortunately, to date, no research based on the FUCL technology has been developed and reported for anti-tumor therapy.
Here, for the rst time, we designed and synthesized a onephoton excitation organic molecular upconversion sensitizer (FUCP-1) based on the FUCL mechanism for deep-seated tumor PDT. A rhodamine derivate is chosen because its rhodamine architecture possesses superior capability of hot-band absorption for generating anti-Stokes emission. In FUCP-1, as illustrated in Fig. 1 , the introduction of a heavy atom (iodine atom) signicantly facilitates the transition of the excited singlet state S 1 to the excited triplet state (T 1 ), also known as intersystem crossing (ISC) during the one-photon upconversion PDT process. The enhanced ISC ability subsequently promoted the production of cytotoxic singlet oxygen ( 1 O 2 ). [38] [39] [40] [41] [42] Different from conventional Stokes excitation, the one-photon driven upconversion process of FUCP-1 is induced by 808 nm excitation from the thermally excited vibrational-rotational energy sublevels of the ground electronic state S t to S 1 and the additional energy is supplied by the heat derived from the Boltzmann distribution of molecules. ($73.7%) aer 808 nm laser irradiation. In addition, while the tumor was covered with 5 mm pork tissue and then exposed to the laser irradiation, the inhibition rate of tumor growth was still up to $50.1%. Importantly, FUCP-1 could be easily cleared from the body within 24 h, demonstrating negligible systematic toxicity during treatment. All these advantages showed that this one-photon excitation molecular upconversion sensitizer FUCP-1 could serve as an ideal phototherapeutic platform for deepseated cancer therapy.
Results and discussion
Synthesis and spectroscopy FUCP-1 was efficiently prepared as outlined in Scheme S1. † Briey, 5-iodo-2,3,3-trimethyl-3H-indole (1) uorescence centered at 750 nm. Meanwhile, under 808 nm excitation, FUCP-1 showed an intense NIR upconversion luminescence (UCL) signal, peaking at 750 nm, which was consistent with the emission upon Stokes excitation (700 nm). The UCL quantum yield (F f ) of FUCP-1 was up to 12.6% in dichloromethane which is superior to that of most nano-materials, favouring the application for image-guided cancer PDT.
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Upconversion luminescence mechanism of FUCP-1
To determine the mechanism for upconversion emission from FUCP-1, the effect of temperature on absorbance and uores-cent intensity (Stokes and anti-Stokes) was rst studied. As shown in Fig. 2a and b, the intensity of absorbance obviously decreased as the solution temperature increased from 0 to 70 C. Accordingly, the maximum uorescence intensity of FUCP-1 rapidly decreased with increasing temperature. It is noteworthy that the UCL intensity of FUCP-1 was signicantly boosted as the solution temperature increased (Fig. 2c) , consistent well with previous reports that higher temperature can facilitate the FUCL process. 37, 46 In addition, the UCL intensity of FUCP-1 under 808 nm excitation showed superior linear dependence on the excitation power density from 0 to 52 mW cm À2 (R 2 ¼ 0.993, Fig. 2d ), suggesting that the UCL emission of FUCP-1 is an one-photon process. In view of the above two characteristics, we thus deduced that the onephoton upconversion luminescence process of FUCP-1 was indeed FUCL. 43, 46, 51, 52 The upconversion luminescence mechanism of FUCP-1 is shown in Fig. 2e . Under low temperature conditions, a large percentage of FUCP-1 is in the zero point vibrational level of the ground electronic state (S 0 ). While the temperature increases, some of the molecules tend to distribute in the thermally vibrational-rotational states (S t ), leading to the absorption coefficient and Stokes emission from S 0 into S 1 to rapidly decline. In contrast, higher temperature facilitates the distribution of FUCP-1 to S t , thereby resulting in excitation transition probabilities for anti-Stokes emission. We also calculated the photon energy of Stokes and anti-Stokes excitation. Obviously, the photon energy of 808 nm (1.53 eV) excitation is much lower than that of 700 nm (1.77 eV) excitation, which could dramatically enhance the anti-bleaching capabilities of dye molecules and reduce photodamage to normal tissue under anti-Stokes excitation.
Then, we conducted a photostability experiment (Fig. 2f) . Aer exposure to continuous 808 nm laser illumination for 20 min (200 mW cm À2 or 800 mW cm
À2
), nearly no photobleaching of the FUCP-1 solution was observed. In sharp contrast, under the same conditions as for traditional Stokes illumination (700 nm, 800 mW cm À2 ), FUCP-1 was dramatically decomposed as indicated by the 70% decline of the absorption intensity in only 6 min (71% for 200 mW cm À2 in 20 min). The result indicates that FUCP-1 during the upconversion process displayed excellent antibleaching capabilities, which is critical for long-term imaging observation and photon-triggered cancer treatment.
O 2 photosensitizing ability of FUCP-1
In order to conrm the heavy atom effect of iodine atoms on the one-photon upconversion process, we then evaluated light- Fig. 3a and b) . Aer exposure to 808 nm laser (800 mW cm À2 ) irradiation, the DPBF absorbance intensity sharply decreased within 240 s in the presence of FUCP-1 (Fig. S9 †) . In sharp contrast, when exposed to the same light dose (800 mW cm À2 , 240 s), negligible 1 O 2 was generated by NRh-1 because of the lack of ISC capacity. DPBF decomposition at 415 nm by FUCP-1 with a 808 nm laser was 3.3-fold that of NRh-1, demonstrating that the introduction of the iodine atom immensely promoted the ISC process (Fig. 3c) . We then investigated whether the temperature could affect the 1 O 2 generation under upconversion excitation. When the solution temperature was boosted from À20 to 25 C, the degradation rates of DPBF in FUCP-1 solution under 808 nm laser irradiation rapidly increased ( Fig. 3d and S10 † 53, 54 As shown in Fig. S11 , † no obvious uores-cence was observed in the groups NRh-1 with and without laser.
In contrast, strong green uorescence was detected in 4T-1 cells treated with FUCP-1 and 808 nm laser irradiation, suggesting that O 2 can be effectively converted to 1 O 2 in cancer cells by FUCP-1 under anti-Stokes excitation. We then further conrmed the species of ROS using 2 0 ,7 0 -dichlorouorescin diacetate (DCFH-DA) which is a well-used ROS capture agent. Aer incubation with DCFH-DA (10 mM) for 30 min, 4T1 cells which were treated with FUCP-1 (5 mM) and 808 nm laser irradiation (800 mW cm À2 , 10 min) showed intense green uores-cence of DCF (Fig. 3e) . In contrast, 4T1 cells treated with NRh-1 with or without 808 nm laser irradiation did not show distinct uorescence, which is in accordance with the result in Fig. S11 . † Notably, the uorescence induced by ROS in 4T1 cells was visibly quenched by NaN 3 (a widely accepted 1 O 2 scavenger), further indicating that the species of ROS generated in the upconversion process by FUCP-1 was indeed 1 O 2 .
Cellular uptake and localization of FUCP-1
Prior to studying the potential PDT ability of FUCP-1, cellular uptake and subcellular localization was investigated in 4T1 cells. As presented in Fig. 4a and S12, † clear upconversion luminescence was detected in 4T1 cells only aer 10 min of incubation with FUCP-1 and the upconversion luminescence rapidly peaked in 2-4 h. This result conrmed that the organic molecular dye FUCP-1 could effectively penetrate into the tumor cells, which is an important factor for in vitro and in vivo PDT. In addition, it was worth noting that the uorescence distribution of FUCP-1 overlapped well with that of MitoTracker Green (a commercial mitochondrial tracking dye) with a high Pearson's correlation coefficient (PC ¼ 0.87) (Fig. 4b) . In contrast, very poor overlapping was observed in the group of Hoechst 33342 (a specic nuclear tracking dye) and FUCP-1 (PC ¼ 0.13). These results demonstrated that FUCP-1 can well localize in mitochondria, presumably as the positive charge of the molecule directing the dye to the mitochondrion. This would result in efficient PDT, as the mitochondrion is of great importance for regulating various metabolic pathways in living cells.
In vitro one-photon upconversion excitation induced cellular toxicity evaluation
To investigate the potential PDT application of FUCP-1 during upconversion excitation, methyl thiazolyltetrazolium (MTT) assay was conducted based on 4T1 cancer cells. As shown in Fig. 5a , FUCP-1 with 808 nm laser irradiation presented superior inhibition of 4T1 cells and the half maximal inhibitory concentration (IC 50 ) was as low as 2.06 mM. In contrast, the groups only treated with FUCP-1 in the dark did not exhibit any obvious cell death, demonstrating its good biocompatibility. Moreover, with the optical density increased from 0 to 1.6 W cm À2 , FUCP-1 displayed signicantly boosted cytotoxicity (Fig. 5b) . Importantly, even under a high optical dose (1.6 W cm À2 , 10 min), the cell viabilities in the absence of FUCP-1 remained over 95%. The low photodamage was mainly due to the negligible absorption of water at this wavelength, well overcoming the defect of 980 nm excitation (water at this wavelength shows obvious absorption) widely used in traditional UCNPs.
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In order to understand the therapeutic mechanism, a ow cytometer was used to investigate the process of cell death. As depicted in Fig. 5c , 4T1 cell growth was not affected by treatments with PBS, FUCP-1 or 808 nm laser irradiation only. However, while 4T1 cells incubated with FUCP-1 were exposed to 808 nm laser irradiation, the percentage of necrotic cells rapidly increased to 32.5%, further demonstrating its promising application in PDT. A live/dead cell co-staining assay, in which the live and dead cells are labelled with green and red uorescence respectively, was then conducted (Fig. 5d, S13 †) . Obviously, 4T1 cells treated with PBS, FUCP-1 or 808 nm laser irradiation showed intense green uorescence. In contrast, 4T1 cells incubated with FUCP-1 (5 mM) followed by exposure to an 808 nm laser exhibited strong red uorescence, intuitively showing the superior PDT ability of FUCP-1.
In vivo antitumor effect for deep-seated tumors
Encouraged by the excellent in vitro PDT performance of FUCP-1, we proceeded to study the anticancer efficacy in vivo. As tumor targeting was a very important characteristic for imageguided in vivo PDT, 57 we rst evaluated the intratumoral accumulation of FUCP-1 in 4T1 tumor-bearing BALB/c mice via intravenous injection. As shown in Fig. 6a , FUCP-1 displayed outstanding tumor targeting and UCL imaging ability. Obviously, at 4 h and 8 h post-injection, the liver region exhibited an intense luminescence signal and then the UCL signal mainly shied to the tumor site. The ex vivo UCL images at 8 h also demonstrated that FUCP-1 could accumulate in the tumor region efficiently (Fig. S14 †) . It was noticeable that the luminescence signal almost disappeared in mice 24 h post-injection, which demonstrated that FUCP-1 can be effectively cleared from the body, thus maximally reducing the long-term toxicity.
To demonstrate the in vivo PDT potential of FUCP-1 for deep-seated tumor imaging, 4T1 tumor-bearing BALB/c mice at 8 h aer intravenous injection (1.2 mg kg À1 of FUCP-1), which was the maximum drug concentration time point at the tumor site, were exposed to 15 min irradiation (Fig. 6b) . 5 mm pork tissue was prepared and used to cover the tumors in one of the treatment groups. During two weeks of therapy, the changes of tumor volumes and mice weights under different treatments (only PBS; FUCP-1 injection; only laser irradiation; FUCP-1 injection + 5 mm pork tissue + laser irradiation; FUCP-1 injection + laser irradiation) were simultaneously recorded. As presented in Fig. 6c , tumor volumes grew rapidly in these mice treated with PBS, FUCP-1 or only 808 nm laser irradiation (800 mW cm À2 , 15 min), suggesting that the tumor growth was not affected by FUCP-1 or 808 nm laser irradiation. By contrast, the irradiated mice at 8 h post-injection exhibited outstanding tumor inhibition. The inhibition rate of tumor growth was as high as $73.7%, showing the prominent antitumor effect of FUCP-1. Importantly, the tumor was also signicantly inhibited by FUCP-1 with 808 nm laser irradiation while 5 mm pork tissue covered the tumors during PDT (the inhibition rate of tumor growth was up to $50.1%), demonstrating the potential of FUCP-1 for deep-seated tumor treatment. These results were also represented using the representative photographs and average tumor weight of isolated tumors from the experimental mice aer different treatments ( Fig. 6d and S15 †) .
Hematoxylin and eosin (H&E) staining of the corresponding histological analysis showed that the treatment of FUCP-1 with 808 nm laser irradiation led to severe cell necrosis. Obviously, tumor tissue was also seriously injured while 5 mm pork tissue covered the tumors in the course of PDT (Fig. 6e) . In contrast, no remarkable tumor tissue damage was observed when the mice were treated with only FUCP-1 or 808 nm laser irradiation. These results maintained good consistency with the data of tumor growth, further indicating that the onephoton driven PDT process of FUCP-1 could effectively result in tumor tissue ablation. In addition, all mice did not show apparent weight variation during the two weeks of therapy, suggesting that there were no negligible side effects caused by FUCP-1 and light irradiation (Fig. 6f) . Histological analysis of the major organs was also performed. No noticeable damage was found from the H&E staining images of the heart, liver, spleen, lung, and kidney (Fig. S16 †) , conrming that FUCP-1 eliminated substantial systemic toxicity in vivo PDT treatment.
Conclusions
In summary, based on the FUCL strategy, we reported the rst one-photon molecular upconversion photosensitizer (FUCP-1) with NIR 808 nm excitation and 750 nm emission for deep PDT. This new upconversion photosensitizer FUCP-1 showed a high UCL quantum yield which could help realize real-time monitoring of in vivo tumor-targeting accumulation. FUCP-1 demonstrated excellent photostability upon 808 nm laser irradiation, overcoming the photobleaching problem of traditional Stokes excitation. In addition, compared to traditional UCNPs which oen suffer from unclear systematic toxicities, FUCP-1 could be easily cleared from the body within 24 h. More importantly, the in vivo PDT of FUCP-1 induced by a 808 nm laser displayed efficient antitumor efficacy while the tumors were covered with 5 mm pork tissue. Therefore, FUCP-1 is promising for photon-driven deep-seated cancer therapy and thus can be utilized as an ideal molecular upconversion platform for the design of multifunctional photosensitizers.
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